Learn about the promising results of triplet therapy in early bladder cancer treatment, offering new hope for patients.

Discover how NCOA6 loss is associated with aggressive prostate cancer and EGFR overexpression, highlighting potential ...

Explore how private sector initiatives are supporting community oncology practices in offering clinical trials, addressing ...

The phase 3 DeLLphi-305 trial showed tarlatamab plus durvalumab significantly improved overall and progression-free survival ...

The combination of osimertinib and savolitinib improves survival in patients with EGFR-mutated NSCLC with MET alterations ...

Sacituzumab govitecan extends survival in advanced endometrial cancer post chemotherapy and immunotherapy, per phase 3 data.

In October, the U.S. Food and Drug Administration (FDA) granted fast track designation to investigational therapies across a range of cancer types, including lung, prostate, gastrointestinal, and ...

Once again, a major clinical trial has shown that for patients with muscle invasive bladder cancer (MIBC) who were ineligible for or decline cisplatin-based chemotherapy before radical cystectomy, ...

The combination of the individualized neoantigen therapy (INT) intismeran autogene plus pembrolizumab (Keytruda) significantly improved the recurrence-free survival (RFS) compared with placebo plus ...

Reducing ICI dose frequency in cancer patients led to more deaths, prompting early trial termination and highlighting risks of less frequent dosing.

The claudin 18.2 (CLDN18.2)-targeting antibody drug conjugate (ADC) sonesitatug vedotin significantly improved overall survival (OS) in patients with previously treated advanced or metastatic CLDN18.2 ...